


ALIENOR

Avastin and weekly paclitaxel use in sex cord-stromal ovarian tumors

A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by maintenance with bevacizumab monotherapy versus weekly paclitaxel followed by observation in patients with relapsed ovarian sex-cord stromal tumors



ALIENOR DESIGN : 60 patients



Population :

Patients with an histologically confirmed diagnosis of **ovarian sex-cord stromal tumor** in relapse after a platinum-based chemotherapy.


Primary objective :

Clinical benefit rate
(non-progression rate after 6 months of treatment)

Stratification

Anterior chemotherapy lines :
1 or 2 vs 3 and more
Platinum Free Interval (PFI)
<12 months vs ≥12 months

ALIENOR Status



- Enrollment period : 36 months
- Treatment + maintenance : 18 months
- Follow-up : 36 months

First Patient In : February 2013
 Last Patient Out of Maintenance : August 2017
 Last Patient Out : August 2020